[Inhibitory effect of suplatast tosilate on eosinophil migration].
Suplatast tosilate has been shown to inhibit generation of Th2-type cytokines in vitro and used in the treatment of allergic diseases. Although the exact mechanism remains unknown, this compound attenuates the eosinophil infiltration in the asthmatic airway. In the present study, we examined whether suplatast tosilate directly modulates eosinophil migration in response to inflammatory mediators in vitro. Suplatast did not modify the spontaneous migration of eosinophils. On the other hand, eosinophil migration in response to PAF (1 microM) was significantly inhibited by 1 microM suplatast. Similarly, IL-5 (100 pM)-induced eosinophil migration was inhibited by 1 microM suplatast. These results suggest that suplatast tosilate inhibits eosinophil locomotion in response to PAF or IL-5 and thereby attenuates infiltration of the cells in allergic inflammation.
Kobayashi
Y
Y
Second Department of Internal Medicine, Saitama Medical School.
Nagata
M
M
Yamamoto
H
H
Sakamoto
Y
Y
D018926:Anti-Allergic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001190:Arylsulfonates / Q000494:pharmacology* / Q000627:therapeutic use; D001249:Asthma / Q000276:immunology*; D002465:Cell Movement / Q000187:drug effects*; D004804:Eosinophils / Q000187:drug effects*; D006633:Histamine Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D015850:Interleukin-6 / Q000494:pharmacology; D010972:Platelet Activating Factor / Q000494:pharmacology; D013452:Sulfonium Compounds / Q000494:pharmacology* / Q000627:therapeutic use
D018926:Anti-Allergic Agents; D001190:Arylsulfonates; D006633:Histamine Antagonists; D015850:Interleukin-6; D010972:Platelet Activating Factor; D013452:Sulfonium Compounds; C073028:suplatast tosilate